Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.56 |
| ▸ | PPARD | Q03181 | 1/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.56 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.55 |
| ▸ | FEN1 | P39748 | 1/20 | 0.55 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.54 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.54 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.54 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4433180 | 0.90 | FFAR1 (0.60) | PTGS1AKR1C3AKR1C2HPGDKDM4E | |
| SCHEMBL4207967 | 0.89 | PTGS1 (0.59) | PTGS1AKR1C3AKR1C2FFAR1PPARD | |
| SCHEMBL4440857 | 0.87 | MMP2 (0.53) | PTGS1AKR1C3AKR1C2HPGDKDM4E | |
| SCHEMBL491853 | 0.85 | PTGS1 (0.58) | PTGS1AKR1C3AKR1C2HPGDKDM4E | |
| SCHEMBL31688954 | 0.85 | FFAR1 (0.63) | HPGDKDM4EALDH1A1SMN1; SMN2FFAR1 | |
| SCHEMBL28032595 | 0.85 | LMNA (0.63) | PTGS1HPGDKDM4EGRIN2DGRIN3B | |
| SCHEMBL29936241 | 0.84 | SLC13A5 (0.61) | PTGS1AKR1C3AKR1C2FFAR1PPARD | |
| SCHEMBL4206771 | 0.84 | SLC13A5 (0.61) | PTGS1AKR1C3AKR1C2FFAR1PPARD | |
| SCHEMBL4217510 | 0.83 | KDM4E (0.68) | PTGS1AKR1C3AKR1C2HPGDKDM4E | |
| Methyl Alcohol SCHEMBL7855784 | 0.83 | ABCC4 (0.62) | PTGS1GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11214564-B2 | Compounds with thymine skeleton for use in medicine | Technische Universität Dresden (DE) | 2022-01-04 | — | — | US | disclosed |
| US-11214564-B2 | Compounds with thymine skeleton for use in medicine | Technische Universität Dresden (DE) | 2022-01-04 | — | — | US | disclosed |
| EP-3819006-A1 | COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE | Technische Universität Dresden (DE) | 2021-05-12 | — | — | EP | disclosed |
| EP-3819006-A1 | COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE | Technische Universität Dresden (DE) | 2021-05-12 | — | — | EP | disclosed |
| US-20210130328-A1 | NOVEL COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE | Technische Universität Dresden (DE) | 2021-05-06 | — | — | US | disclosed |
| US-20210130328-A1 | NOVEL COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE | Technische Universität Dresden (DE) | 2021-05-06 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2005092062-A2 | COMPOUNDS FOR NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130328-A1 | NOVEL COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE | TMSB10, TMSB4X, TBCA | PTGS1 1292/4885AKR1C3 3437/4885AKR1C2 3686/4885 |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | PTGS1 2198/4885AKR1C3 570/4885AKR1C2 653/4885 |
| US-11214564-B2 | Compounds with thymine skeleton for use in medicine | TMSB10, TMSB4X, TBCA | PTGS1 1440/4885AKR1C3 3270/4885AKR1C2 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.